Abstract:Autoreactive B cells are characterized by their ability to secrete autoantibodies directed against self-peptides. During the last decade, it has become increasingly apparent that B lymphocytes not only produce autoantibodies but also exert important regulatory roles independent of their function as antibody-producing cells. This is especially relevant in the context of autoimmunity, because autoreactive B cells have been shown to possess the ability to activate pathogenic T cells, to produce pro-inflammatory cytokines, and to promote the formation of tertiary lymphoid tissue in target organs. The production of monoclonal antibodies against B-cell-surface molecules has facilitated the characterization of several distinct B lymphocyte subsets. These cell-surface molecules have not only served as useful cell differentiation markers but have also helped to unravel the important biological functions of these cells. Some of these molecules, all of which are expressed on the cell surface, have proven to be effective therapeutic targets. In both animal models and in clinical assays, the efficient elimination of B lymphocytes has been shown to be useful in the treatment of rheumatoid arthritis and other autoimmune diseases. The treatment of most rheumatic autoimmune diseases relies mainly on the use of cytotoxic immunosuppressants and corticosteroids. Although this has resulted in improved disease survival, patients may nonetheless suffer severe adverse events and, in some cases, their relapse rate remains high. The increasing need for safer and more effective drugs along with burgeoning new insights into the pathogenesis of these disorders has fueled interest in biological agents; clinical trials involving the B-cell depletion agent rituximab have been especially promising. This article reviews the current knowledge of B-cell biology and pathogenesis as well as the modern therapeutic approaches for rheumatic autoimmune diseases focusing in particular on the targeting of B-cell-specific surface molecules and on the blocking of B-cell activation and survival.

B cell depletion in autoimmune rheumatic diseases

Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases

B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia

B cell depletion therapy in autoimmune diseases.

B-Cell Depletion and Repopulation in Autoimmune Diseases

Effective B Cell Depletion with Rituximab in the Treatment of Autoimmune Diseases

[Rituximab and autoimmune disorders therapy]

The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases

Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases

Rituximab in autoimmune hematologic diseases: not just a matter of B cells

B-cell depletion in autoimmune diseases

Rituximab in B-cell disorders other than non-Hodgkin's lymphoma

Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders

CD20+ B Cell Depletion in Systemic Autoimmune Diseases: Common Mechanism of Inhibition or Disease-Specific Effect on Humoral Immunity?

The potential utility of B cell-directed biologic therapy in autoimmune diseases

Use of Rituximab in Rheumatoid Arthritis

Long-Lived Plasma Cells in Autoimmunity: Lessons from B-Cell Depleting Therapy

Targeting B Cells and Plasma Cells in Autoimmune Diseases

Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis

Translational Mini‐Review Series on B Cell‐Directed Therapies: The pathogenic role of B cells in autoantibody‐associated autoimmune diseases – lessons from B cell‐depletion therapy

Clinical Application of Rituximab in Rheumatoid Arthritis